Organization | Zhejiang Genfleet Therapeutics Co., Ltd.

Zhejiang Genfleet Therapeutics Co., Ltd. Report issue

For profit Phase 2

Founded: Shanghai China (2017)

Organization Overview

First Clinical Trial

2020

NCT04588922

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

GenFleet Therapeutics (Australia) Pty Ltd. | Genfleet Therapeutics (Shanghai) Inc. | Zhejiang Genfleet Therapeutics Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (11)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

gfh009 (2 trials)

gfh018 (3 trials)

gfh312 (3 trials)

gfh925 (2 trials)

gfs101a (1 trial)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

toripalimab (LOQTORZ) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hematologic Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 11